Business Context and Reporting Period
Company: Healthcare Realty Trust Incorporated
Filing Type: Form 8-K (Current Report)
Date of Report: December 17, 2025
Event: Entry into a Material Definitive Agreement regarding an Equity Offering Program.
Key Financial Metrics and Transaction Details
- Offering Size: Up to $1,000,000,000 aggregate offering price of Class A common stock.
- Transaction Structure: "At-the-market" offerings and privately negotiated transactions via Equity Distribution Agreements, alongside Master Forward Confirmations allowing for forward sale agreements.
- Compensation: Sales agents and forward sellers are entitled to compensation of up to 2.00% of gross proceeds or gross sales price.
- Use of Proceeds: General corporate purposes, including acquisition, development, and redevelopment of healthcare facilities, and contributions to the Operating Partnership (OP).
- Debt/Liquidity Impact: Proceeds may be used to repay borrowings under the Company's Unsecured Credit Facility.
Material Changes and Agreements
On December 17, 2025, the Company entered into separate Equity Distribution Agreements and Master Forward Confirmations with a syndicate of 16 sales agents and 15 forward purchasers. This establishes a new mechanism for the Company to sell shares from time to time. The filing notes that affiliates of the sales agents are also lenders under the Company's existing Unsecured Credit Facility.
Guidance, Outlook, and Risks
- Management Commentary: The Company has no obligation to sell any shares under the agreements and may suspend solicitation at any time.
- Related Party Transactions: If proceeds are used to repay the Unsecured Credit Facility, affiliates of the sales agents (who are also lenders) may receive a portion of such proceeds.
- Risks: The offering is subject to customary terms and conditions. Sales are contingent on market conditions and the Company's discretion.
Investor Verification Checklist
- Verify the specific terms of the Equity Distribution Agreements and Master Forward Confirmations in Exhibits 1.1 and 1.2.
- Monitor the Company's Form S-3ASR (File No. 333-273784) and associated prospectus supplements for actual sales activity.
- Assess the impact of potential share dilution on existing shareholders given the $1 billion capacity.
- Review the Company's capital allocation strategy to determine if proceeds will be used for debt reduction or new facility acquisitions.